Lilly/Icos Cialis Development Strategy: FDA Delays Phase IIIs – Go Overseas
Lilly/Icos’ Cialis NDA was based on Phase III studies conducted outside the U.S. after FDA advised the firm at an end-of-Phase II meeting to delay pivotal studies until potential testicular toxicity could be investigated, FDA review documents show.